Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 for neuropsychiatric indications; and Verdiperstat, a product for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.
Revenue of Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
Revenue in 2023 (TTM): $
According to Biohaven Pharmaceutical Holding Company Ltd.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Biohaven Pharmaceutical Holding Company Ltd.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-3,369,000 | $-429,139,000 | $-409,551,000 | $-408,168,000 |
| 2022 | $ | $-1,386,000 | $-462,799,000 | $-569,841,000 | $-570,279,000 |
| 2021 | $462.51 M | $370.85 M | $-217,507,000 | $-212,430,000 | $-213,796,000 |
| 2020 | $ | $-72,000 | $-114,434,000 | $-118,668,000 | $-118,668,000 |
| 2019 | $ | $ | $-479,122,000 | $-528,386,000 | $-528,805,000 |
| 2017 | $ | $ | $ | $ | $ |